Press Release: SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

Dow Jones11-12

Continued adoption of the QUELIMMUNE(R) therapy yielded 247% increase in net revenue compared to the third quarter of 2025

Achieved nearly 75% enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with acute kidney injury (AKI) receiving CRRT

Reported statistically significant higher survival for QUELIMMUNE-treated patients versus comparator cohort at ASN Kidney Week 2026 late-breaking presentation

Fulfilled FDA post-approval requirements for SAVE Registry study

Webcast today at 4:30 p.m. Eastern Time

DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today financial results for the three months ended September 30, 2026, and provided business updates on key initiatives.

"The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications, " said Eric Schlorff, CEO of SeaStar Medical. "And we continue to build momentum in educating the critical care pediatric health care community. In addition to several medical meeting presentations by Dr. Kevin Chung, our CMO, we have already begun sharing with critical care professionals the statistically significant higher survival in QUELIMMUNE-treated patients that was presented at the late-breaking presentation at ASN Kidney Week 2026."

Mr. Schlorff continued, "The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval. Our Breakthrough Device Designation for this indication will also enable a priority review once we submit the final module with the NEUTRALIZE-AKI pivotal trial results, provided a positive outcome in the trial."

Key Business Highlights

Since the beginning of the third quarter, SeaStar Medical's key business updates include the following:

   -- Expanded the use of the QUELIMMUNE (SCD-PED) therapy as a treatment for 
      ultra-rare sepsis-associated AKI in pediatric patients receiving renal 
      replacement therapy (RRT), increasing net revenue 247% to $635 thousand 
      compared to the third quarter of 2025. Gross profit margins remained at 
      greater than 90%. 
 
   -- Presented at ASN Kidney Week 2026 real-world pediatric patient survival 
      data from the commercial use of the QUELIMMUNE therapy based on results 
      from the SAVE Registry of 50 critically ill pediatric patients with 
      life-threatening sepsis-associated AKI. The QUELIMMUNE (SCD-PED) therapy 
      group showed statistically significant higher survival in the primary 
      analysis at Day 60, Day 90, and at hospital discharge versus comparator 
      cohorts. No device-related adverse events occurred in patients treated 
      with the QUELIMMUNE (SCD-PED) therapy. 
 
   -- Fulfilled FDA post-approval requirements for the SAVE Registry study for 
      QUELIMMUNE for the treatment of sepsis-associated AKI in pediatric 
      patients. FDA's decision now enables hospitals to employ the QUELIMMUNE 
      therapy without the research infrastructure that the SAVE Registry 
      demanded, which may increase availability for these critically ill 
      pediatric patients. 
 
   -- Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial 
      evaluating the SCD therapy as a potential treatment for adult patients 
      with AKI in the ICU receiving continuous renal replacement therapy 
      (CRRT). The trial is nearly 75% enrolled, with 251 of 339 patients 
      enrolled to date. The NEUTRALIZE-AKI pivotal clinical trial is expected 
      to complete enrollment by mid-year 2027. 
 
   -- Completed and submitted to the FDA the first module of a modular 
      premarket approval $(PMA)$ application for the potential approval of the 
      SCD therapy as a treatment for adult patients with AKI in the ICU 
      receiving CRRT. 
 
   -- Granted Breakthrough Device Designation from the FDA for the SCD therapy 
      for the treatment of hyperinflammation in adult patients with sepsis or a 
      septic condition. The Breakthrough Device Designation is a regulatory 
      pathway designed to provide for accelerated development, assessment, and 
      review for FDA approval of medical devices and potentially more effective 
      treatments of life-threatening or irreversibly debilitating diseases or 
      conditions. This marks the seventh Breakthrough Device Designation for 
      the SCD therapy thus far across a range of indications. 
 
   -- Received dedicated International Classification of Diseases, 10th 
      Revision, Procedure Coding System (ICD-10-PCS codes) from the Centers for 
      Medicare & Medicaid Services (CMS). These codes, which took effect on 
      October 1, 2026, enable administrative, billing, and statistical 
      reporting for the use of SeaStar Medical's SCD therapy in patients with 
      AKI requiring RRT in the inpatient hospital setting. 

Financial Results for the Third Quarter 2026

Net revenue for the three months ended September 30, 2026, and 2025, was approximately $0.6 million and $0.2 million, respectively, reflecting increased sales of QUELIMMUNE.

Cost of goods sold for the three months ended September 30, 2026, and 2025, was $48 thousand and $14 thousand respectively.

Research and development expenses for the three months ended September 30, 2026, and 2025, were $3.6 million and $1.9 million, respectively. The increase in research and development expenses was primarily driven by increased clinical research activities for the NEUTRALIZE-AKI pivotal clinical trial, SCD development costs, personnel, and payroll costs.

General and administrative expenses for the three months ended September 30, 2026, and 2025, were approximately $1.6 million and $1.9 million, respectively. The decrease in general and administrative expenses was the result of a decline in personnel, legal, audit, and SEC-related costs, partially offset by increased professional services, director fees, and franchise taxes.

Other income (net) for the three months ended September 30, 2026, was approximately $0.1 million compared to other expense of approximately $0.1 million for the three months ended September 30, 2025.

Net loss for the three months ended September 30, 2026, was approximately $4.5 million, or $1.03 per share on approximately 4.4 million weighted-average shares outstanding. This compares with a net loss of approximately $3.5 million, or $1.30 per share, on approximately 2.7 million weighted-average shares outstanding for the three months ended September 30, 2025.

Cash at September 30, 2026, was $4.0 million, which does not include the $3.3 million of gross proceeds from warrant exercises that occurred in October 2026. This compares to cash of $12.0 million at December 31, 2025.

SeaStar Medical Third Quarter Financial Results Conference Call

 
Date/Time:                Wednesday, November 11, 2026, at 4:30 p.m. ET / 2:30 
                           p.m. MT 
 
Webcast:                  The live webcast and replay can be found here. 
 
Register for the call:    Preregistration is required to attend the live call 
                          and can be accessed here. A pin code and dial in 
                          number will be provided with registration. 
 
 

A replay of the call will be available after 7:30 p.m. ET and can be accessed here.

About QUELIMMUNE

The QUELIMMUNE(R) (SCD-PED) therapy is being commercialized for children with AKI and sepsis or a septic condition weighing 10 kilograms or more and aged <=22 years who are on antibiotics and being treated in the ICU with RRT. It was approved in February 2024 under a Humanitarian Device Exemption application.

Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge.

The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device $(SCD)$ therapy and could have broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.

QUELIMMUNE was approved by FDA under a Humanitarian Device Exemption based on safety and probable benefit. The effectiveness of this device for this use has not been demonstrated. Adverse reactions observed in clinical studies include hypotension, hypothermia, tachycardia, hyperglycemia, and thrombocytopenia. Additional risks may include blood loss or extracorporeal circuit complications. QUELIMMUNE must be used with citrate anticoagulation.

For complete risk information, please see: https://seastarmedical.com/quelimmune

About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy

The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient's body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing CRRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future CRRT, including dialysis, and prevent loss of life.

About NEUTRALIZE-AKI Pivotal Trial

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device -- a randomIZEd clinical trial in AKI) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving CRRT. The trial's primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.

About Acute Kidney Injury (AKI) and Hyperinflammation

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical's first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for seven therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, SeaStar Medical's expectations with respect to expanded access to critically ill pediatric patients as a result of the fulfillment of the SAVE Registry requirements, the potential benefit from the SCD-PED therapy with a favorable observed safety profile; anticipated improved survival in real-world critical care practice; anticipated adoption our products; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical's control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical's Annual Report on Form 10-K, including those under the "Risk Factors" section therein and in SeaStar Medical's other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

-- Financial Tables to Follow --

 
 
                  SeaStar Medical Holding Corporation 
                  Condensed Consolidated Balance Sheets 
         (in thousands, except for share and per-share amounts) 
 
                            September 30, 2026     December 31, 2025 
                           --------------------   ------------------- 
                               (unaudited) 
                               ASSETS 
Current assets 
  Cash                      $             3,989    $           11,980 
  Accounts receivable, 
   net of allowance for 
   credit losses of $2 
   and $3, respectively                     178                   237 
  Inventory                                  45                    66 
  Prepaid expenses                          755                 1,297 
    Total current assets                  4,967                13,580 
  Other assets                              343                   578 
                               ----------------       --------------- 
    Total assets            $             5,310    $           14,158 
                               ================       =============== 
 
           LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT) 
Current liabilities 
  Accounts payable          $             1,467                   948 
  Accrued expenses                        3,373                 2,268 
  Notes payable, net of 
   deferred financing 
   costs                                     --                   525 
  Liability classified 
   warrants                                   1                     1 
                               ----------------       --------------- 
    Total current 
     liabilities                          4,841                 3,742 
                               ----------------       --------------- 
    Total liabilities                     4,841                 3,742 
                               ----------------       --------------- 
 
Commitments and 
contingencies 
 
Stockholders' equity 
  Preferred stock - 
  $0.0001 par value per 
  share, 10,000,000 
  shares authorized at 
  September 30, 2026 and 
  December 31, 2025; no 
  shares issued and 
  outstanding at 
  September 30, 2026 and 
  December 31, 2025                          --                    -- 
  Common stock - $0.0001 
   par value per share; 
   425,000,000 and 
   450,000,000 shares 
   authorized at 
   September 30, 2026 and 
   December 31, 2025, 
   respectively; 
   4,461,965 and 
   3,844,613 shares 
   issued and outstanding 
   at September 30, 2026 
   and December 31, 2025, 
   respectively                               4                     4 
  Additional paid-in 
   capital                              163,959               162,126 
  Accumulated deficit                  (163,494)             (151,714) 
    Total stockholders' 
     equity                                 469                10,416 
                               ----------------       --------------- 
    Total liabilities and 
     stockholders' 
     equity                 $             5,310    $           14,158 
                               ================       =============== 
 
 
 
 
                  SeaStar Medical Holding Corporation 
             Condensed Consolidated Statements of Operations 
                               (unaudited) 
         (in thousands, except for share and per-share amounts) 
 
                      Three Months Ended         Nine Months Ended 
                         September 30,             September 30, 
                    -----------------------   ----------------------- 
                       2026         2025         2026         2025 
                    ----------   ----------   ----------   ---------- 
 
Net revenue         $      635   $      183   $    1,745   $      814 
Cost of goods sold          48           14          148           41 
                     ---------    ---------    ---------    --------- 
    Gross profit           587          169        1,597          773 
                     ---------    ---------    ---------    --------- 
Operating 
expenses 
Research and 
 development             3,574        1,850        8,438        5,318 
General and 
 administrative          1,594        1,898        5,134        4,614 
    Total 
     operating 
     expenses            5,168        3,748       13,572        9,932 
                     ---------    ---------    ---------    --------- 
Loss from 
 operations             (4,581)      (3,579)     (11,975)      (9,159) 
                     ---------    ---------    ---------    --------- 
Other income 
(expense) 
Interest income             54          107          214          200 
Interest expense            (2)          --          (16)         (18) 
Other financing 
 costs                      --           --           --         (298) 
Change in fair 
 value of warrants 
 liability                  --           --           --           32 
    Total other 
     income 
     (expense), 
     net                    52          107          198          (84) 
                     ---------    ---------    ---------    --------- 
Loss before 
 provision for 
 income taxes           (4,529)      (3,472)     (11,777)      (9,243) 
Provision for 
 income taxes               --           --            3            3 
                     ---------    ---------    ---------    --------- 
Net loss            $   (4,529)  $   (3,472)  $  (11,780)  $   (9,246) 
                     =========    =========    =========    ========= 
Net loss per share 
 of common stock, 
 basic and 
 diluted            $    (1.03)  $    (1.30)  $    (2.85)  $    (5.96) 
                     =========    =========    =========    ========= 
Weighted-average 
 shares 
 outstanding, 
 basic and 
 diluted             4,390,541    2,669,340    4,132,784    1,551,212 
                     =========    =========    =========    ========= 
 
 
 
 
                   SeaStar Medical Holding Corporation 
              Condensed Consolidated Statements of Cash Flows 
                                (unaudited) 
 
                                    Nine Months Ended September 30, 
                                --------------------------------------- 
                                       2026                  2025 
                                ------------------      --------------- 
 
Cash flows from operating 
activities 
  Net loss                       $         (11,780)              (9,246) 
  Adjustments to reconcile 
  net loss to net cash used 
  in operating activities                       --                   -- 
    Amortization of deferred 
     financing costs                            16                   18 
    Change in fair value of 
     liability classified 
     warrants                                   --                  (32) 
    Shares issued for the 
     standby equity purchase 
     agreement commitment fee                   --                  298 
    Stock-based compensation                   155                  554 
  Change in operating assets 
  and liabilities 
    Accounts receivables, net                   59                 (109) 
    Inventory                                   21                  (83) 
    Prepaid expenses                           542                1,028 
    Other assets                               235                  236 
    Accounts payable                           519               (1,028) 
    Accrued expenses                         1,105               (1,141) 
                                    --------------          ----------- 
Net cash used in operating 
 activities                                 (9,128)              (9,505) 
                                    --------------          ----------- 
 
Cash flows from financing 
activities 
  Proceeds from issuance of 
   shares                                    1,678               14,337 
  Proceeds from exercise of 
   warrants                                     --                1,818 
  Proceeds from issuance of 
   pre-funded warrants                          --                5,886 
  Payment of notes payable                    (541)                (592) 
                                    --------------          ----------- 
Net cash provided by financing 
 activities                                  1,137               21,449 
                                    --------------          ----------- 
Net increase in cash                        (7,991)              11,944 
Cash, beginning of period                   11,980                1,819 
                                    --------------          ----------- 
Cash, end of period              $           3,989       $       13,763 
                                    ==============          =========== 
 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment